Amgen Inc (AMGN)

163.14
2.73 1.70
NASDAQ : Health Care
Prev Close 160.41
Open 162.50
Day Low/High 161.90 / 163.60
52 Wk Low/High 130.09 / 181.81
Volume 3.49M
Avg Volume 3.79M
Exchange NASDAQ
Shares Outstanding 735.89M
Market Cap 119.24B
EPS 10.30
P/E Ratio 15.82
Div & Yield 4.60 (2.80%)

Latest News

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

The Bulls Are Back in Town

The rally finally shows up, bringing much optimism.

Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES

Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES

Online News Resource Highlights Importance of Patient and Care Team Dialogue

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Jim Cramer on What's Next for Amgen Shares

Jim Cramer on What's Next for Amgen Shares

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer sheds light on what's next for Amgen AMGN shares following its downgrade by Jefferies.

Amgen Receives Hold Rating at Jefferies -- Jim Cramer Says It Could Be a Battleground

Amgen Receives Hold Rating at Jefferies -- Jim Cramer Says It Could Be a Battleground

Jefferies lowered its rating on Amgen stock.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

As Biotech Roars Back, Amgen Remains Dirt Cheap

As Biotech Roars Back, Amgen Remains Dirt Cheap

The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma

XGEVA is Currently Indicated for the Prevention of Skeletal-Related Events Known as Bone Complications in Patients With Solid Tumors

Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

Preclinical Results for Mcl-1 Inhibitor for Multiple Myeloma Accepted as Oral Presentation

Taser, AMD, Amgen, Old Republic :'Mad Money' Lightning Round (3/30/17)

Taser, AMD, Amgen, Old Republic :'Mad Money' Lightning Round (3/30/17)

Why Jim Cramer likes Taser, Advanced Micro Devices, Amgen and more.

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

This month's resilience in the market has a lot to do with short squeezes in big tech names.

FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application

FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application

Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval

Amgen Awards Three Golden Tickets For LabCentral Residency

Amgen Awards Three Golden Tickets For LabCentral Residency

Innovative Start-Up Companies Receive One-Year Free Lab Space

European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases

First Biosimilar Adalimumab Approved in the European Union

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

4 Health Care Charts Signaling Buys: Pfizer, Amgen Included

Obamacare? Trumpcare? These stocks don't care.

These 4 Healthcare Charts Are Signaling Buys

These 4 Healthcare Charts Are Signaling Buys

Here's a rundown of four technical setups that are showing solid trading potential.

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View

Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View

Cramer shares his views on how the market had a slow, pre-Trump kind of day, and also discusses the next step in Adobe's tech surge.

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients

Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients

Results From Two Studies Show Approximately 80 Percent of Prescription Claims in the U.S. Are Initially Rejected

Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study

Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study

Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial